Shandong Xinhua Pharmaceutical Company Limited (HKG: 0719)

Market Cap	8.76B
Revenue (ttm)	8.77B
Net Income (ttm)	528.77M
Shares Out	682.41M
EPS (ttm)	0.77
PE Ratio	6.83
Forward PE	n/a
Dividend	0.27 (5.18%)
Ex-Dividend Date	Sep 4, 2024

Volume	960,000
Open	5.25
Previous Close	5.31
Day's Range	5.20 - 5.29
52-Week Range	4.80 - 6.51
Beta	-0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Shandong Xinhua Pharmaceutical Company

Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic drugs; cardiovascular and cerebrovascular drugs; anti-infective drugs and central nervous drugs; and other drugs. It engages in the development of real estate business. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1943
• Employees: 7,104
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0719

Financial Performance

In 2023, Shandong Xinhua Pharmaceutical Company's revenue was 8.10 billion, an increase of 7.97% compared to the previous year's 7.50 billion. Earnings were 496.51 million, an increase of 20.79%.

Financial numbers in CNY